Condition: Non Small Cell Lung Cancer · RET Gene Mutation · MET Amplification · Sponsor: Hunan Province Tumor Hospital
This is an open-label, single-arm, dose-escalation, multicenter phase I/II clinical trial. The primary endpoints of this study were to evaluated the safety, tolerability, pharmacokinetic profile and preliminary efficacy of HE003 in combination with osimertinib in patients with advanced solid tumors who have failed previous standard therapy. The secondary endpoints of this study were to evaluated the efficacy HE003 in combination with osimertinib in patients with advanced solid tumors who have failed previous standard therapy.
This description comes directly from the study's public registry record.
Yongchang C Zhang, MD · +8613873123436 · zhangyongchang@csu.edu.cn
Nong C Yang, MD · +8613873123436 · yangnong0217@163.com
Always discuss trial participation with your own doctor first.
| Hunan Cancer Hospital | Changsha, Hunan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06109558